Thanks Ritz. I don’t know what the results will show. But if we can show a reduction in mortality, the case for Leronlimab will be thunderous. The discussion by the DSMC leads me to believe that Leronlimab is showing efficacy.
However my reason to unblind is based on what Nader said a few conferences ago. He said that both the Brits and the Philippines among others are awaiting the data from the interim S/C analysis. I think those “FDAs” will have a less compromised and more pragmatic review, some type of authorization should come forth. But Nader can get a better understanding and feeling from both of these countries during their upcoming meetings.
Best to you.